eptinezumab   Click here for help

GtoPdb Ligand ID: 10694

Synonyms: ALD-403 | ALD403 | eptinezumab-jjmr | Vyepti®
Approved drug
eptinezumab is an approved drug (FDA (2020), EMA (2022))
Compound class: Antibody
Comment: Eptinezumab is a humanized IgG1 anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of migraine [6]. It was developed by Lundbeck and their subsidiary Alder Biopharmaceuticals (Alderbio). The INN record for eptinezumab indicates that it binds to CALCA (α-CGRP) and CALCB (β-CGRP). Peptide sequence alignment using NCBI BLAST Protein reveals 100% matches with sequences claimed in Alderbio's patent WO2012162257A2, and distinguish eptinezumab as the monoclonal referred to as Ab5 in the patent document.

CGRP plays an important role in migraine pathophysiology [2], and both the CGRP peptide and its receptor (CGRPR) are targets of anti-migraine therapeutics [1,4-5]. Eptinezumab is the fourth anti-CGRP pathway monoclonal to reach the clinic: the others are erenumab (anti-CGRPR), galcanezumab (anti-CALCA/B) and fremanezumab (anti-CALCA/B). These antibodies are used as alternatives to CGRPR antagonists such as ubrogepant (FDA approved in 2019).
No information available.
Summary of Clinical Use Click here for help
Eptinezumab (brand name Vyepti) was granted FDA approval in February 2020, as a preventive treatment of migraine in adults. Vyepti is delivered by intravenous infusion, once every 3 months, with a recommended dose of 100mg.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02559895 A Multicenter Assessment of ALD403 in Frequent Episodic Migraine Phase 3 Interventional Alder Biopharmaceuticals, Inc. PROMISE-1 trial.
NCT02974153 Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine Phase 3 Interventional Alder Biopharmaceuticals, Inc. PROMISE-2 trial.